<DOC>
	<DOCNO>NCT01625182</DOCNO>
	<brief_summary>The study design evaluate efficacy safety fingolimod treatment chronic inflammatory demyelinate polyradiculoneuropathy compare placebo .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Fingolimod 0.5 mg Orally Once Daily Versus Placebo Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients .</brief_title>
	<detailed_description>This study double-blind , randomize , multicenter , placebo-controlled , parallel-group study patient diagnosis chronic inflammatory demyelinate polyradiculoneuropathy treat IVIg , corticosteroid , therapy prior study entry . Patients meet eligibility criterion randomly assign ratio 1:1 receive oral fingolimod ( 0.5 mg/day ) match placebo . The study consist 3 period : Screening Period , Double-blind Treatment Period Follow-up Period discontinuation study drug treatment . Patients complete study option enter extension .</detailed_description>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria write informed consent must obtain assessment perform The diagnosis CIDP use definition EFNS/PNS Task Force First Revision . Patients must either clinical diagnosis CIDP fulfil clinical inclusion criterion typical CIDP one follow atypical form CIDP : pure motor , asymmetrical ( MADSAM [ LewisSumner syndrome ] ) , IgA IgG ( IgM ) MGUS paraprotein associate . All patient must also fulfill clinical exclusion criterion definite electrodiagnostic criterion EFNS/PNS Task Force First Revision . disability define INCAT Disability Scale score 19 , INCAT score 0 , document history disability sufficient require treatment within past 2 year follow reduction interruption CIDP treatment receive IVIg treatment ( minimal dose equivalent 0.4 g/kg every 4 week minimum 12 week ) corticosteroid ( minimal dose equivalent prednisone 10 mg/day ) treatment prior screen visit history document clinically meaningful deterioration confirm clinical examination therapy upon interruption reduction therapy within 18 month prior Screening stable CIDP symptom 6 week randomization Exclusion Criteria chronic demyelinating neuropathy , include : Distal Acquired Demyelinating Symmetric Neuropathy ( DADS ) Multifocal Motor Neuropathy ( MMN ) pure sensory CIDP hematopoietic malignancy except MGUS condition pathogenesis neuropathy may different CIDP : Lyme disease , POEMS syndrome , osteosclerotic myeloma , Castleman 's disease treatment plasma exchange within 2 month randomization , immunosuppressive/chemotherapeutic medication : azathioprine , cyclophosphamide , cyclosporine , mycophenolate , etanercept , methotrexate tacrolimus immunosuppressive drug within 6 month randomization 5 halflives ( whichever later ) , Rituximab 2 year prior randomization ( patient receive rituximab 1 2 year Bcell level within normal range ) , cytotoxic immunosuppressive medication sustain effect ( include mitoxantrone , alemtuzumab , cladribine ) time , hematopoietic stem cell transplantation time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic inflammatory demyelinate polyradiculoneuropathy , CIDP , FTY720 , fingolimod .</keyword>
</DOC>